Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU

Cancer

Volumn 77, Issue 3, 1996, Pages 441-451

  Gamelin, Erick C ^a   Danquechin Dorval, Etienne M ^b   Dumesnil, Yvan F ^c   Maillart, Philippe J ^a   Goudier, M J ^d   Burtin, Pascal C ^e   Delva, Remy G ^a   Lortholary, Alain H ^a   Gesta, Paul H ^f   Larra, Francis G ^a  

^a CENTRE PAUL PAPIN   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c Centre Hospitalier de Nîmes   (France)

^d Centre Hospitalier de Lorient   (France)

^e HÔTEL DIEU   (France)

^f Grp Multicentrique Pays de Loire   (France)

Author keywords

5 fluorouracil pharmacokinetics; chemotherapy; colorectal cancer; dose adjustment; dose intensity

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BOLUS INJECTION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MEDICAL RECORD; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIODIAGNOSIS;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, PARENTERAL; LEUCOVORIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 13344269002     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO;2-N     Document Type: Article

References (38)

1. Arbuck SG. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 1989;63:1036-44.
2. Ardalan B, Chua L, vTian E, Reddy R, Srudhar K, Benedetto P, et al. A phase II study of weekly 24 hour infusion with high dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991;9:625-30.
3. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 1994;10:1517-22.
4. Bruckner HW, Motwani BT. Chemotherapy of advanced cancer of the colon and rectum. Semin Oncol 1991;18:443-61.
5. Diaz-Rubio E, Aranda E, Martin M, Gonzales-Mancha R, Gonzales-Larriba J, Barneto I. Weekly high dose infusion of 5-fluorouracil in advanced colorectal cancer. Eur J Cancer 1990;26:727-9.
6. Drewinko B, Yang LY. Cellular basis for the inefficacy of 5-FU in human colon carcinoma. Cancer Treat Rep 1985;69:1391-8.
7. Erlichman C, Fine S, Elhakim T. Plasma pharmacokinetic of 5-FU given by continuous infusion with allopurinol. Cancer Treat Rep 1986;70:903-4.
8. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, et al. Population study of dihydro pyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994;12:2248-53.
9. Fleming R, Milano G, Thyss A, Etienne MC, Renee N, Schneider M, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992;52:2899-902.
10. Fraile RL, Baker LH, Buroker TR, Horwitz J, Vaitkevicius VK. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 1980;40:2223-28.
11. Gamelin E, Hanes L, Larra F, Turcant A, Allain P, Maillart P, et al. Toxicité cardiaque aiguë du 5-fluorouracile: corrélation pharmacocinétique. Bull Cancer 1991;78:1147-53.
12. Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: a potentially more common pharmacogenetic syndrome. Cancer 1991;68:499-501.
13. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between Dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels math evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990;50:197-201.
14. Hillcoat BL, McCulloch PB, Figueredo AT, Ehsan MH, Rosenfeld JM. Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer 1978;38:719-24.
15. Hougton JA, Williams LG, de Graaf SSM, Cheshire PJ, Rodman JH, Maneval DC, et al. Relationship between dose rate of (6RS) leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylene tetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts. Cancer Res 1990;50:3493-3502.
16. Hryniuk WM, Figueredo A, Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 1987;14:3-11.
17. Hull WE, Port RE, Herrmann R, Britsch B, Kunz W. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res 1988;48:1680-8.
18. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-atlantic oncology program study. J Clin Oncol 1989;7:425-32.
19. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993;53:5433-8.
20. Machover D, Goldschmidt E, Chollet P. Treatment of advanced colorectal and gastric adenocarcinoma with 5-fluorouracil and high dose folinic acid. J Clin Oncol 1986;4:685-96.
21. McDermott BJ, VandenBerg HW, Murphy RF. Non linear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. Cancer Chemother Pharmacol 1982;9:173-8.
22. Milano G, Roman P, Khater P, Frenay M, Renee N, Namer M. Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int J Cancer 1988;41:537-41.
23. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman PJ. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
24. Nguyen-Pamart M, Trupin-Bar N. Isolated perfused rat liver. A model for the study of hepatic metabolism of drugs: example of 5-fluorouracil. Bull Cancer 1980;75:551-6.
25. Pinedo HM, Peters GFJ. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988;6:1653-64.
26. Poon MA, O'Connell MJ, Wieand HS. Biochemical modulation of fluorouracil with Leucovorin: confirmatory evidence of improved efficacy in advanced colorectal cancer. J Clin Oncol 1991;9:1967-72.
27. Rougier P, Paillot B, Laplanche A, Morvan F, Benhamed M, Seitz JF, et al. End results of a multicentric randomized trial comparing 5-FU in continuous systemic infusion (CI) to bolus administration (B) in measurable metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 1992;163:465.
28. Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 1989;59:287-90.
29. Seifert P, Baker LH, Reed ML, Vaitkevicius VK. Comparison of continuously infused 5-fluorouracil with bolus injection in the treatment of patients with colorectal carcinoma. Cancer 1975;36:123-8.
30. Seitz JF, Cano JP, Rigault JP, Aubert C, Carcassonne C. Chimiothérapie des cancers digestifs étendus par le 5-fluorouracile: relations entre la réponse clinique et la clairance plasmatique du mpédicament. Gastroenterol Clin Biol 1983;7:374-80.
31. Shah A, MacDonald W, GoLdie J, Gudauskas G, Brisebois B. 5-FU infusion in advanced colorectal cancer: a comparison of three dose schedules. Cancer Treat Rep 1985;69:739-42.
32. Spicer DV, Ardalan B, Daniels JR, Silberman H, Johnson K. Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics. Cancer Res 1988;48:459-61.
33. Thyss A, Milano G, Renee N, Vallicioni J, Schneider M, Demard F. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 1986;16:64-6.
34. Trump DL, Egorin MJ, Forrest A, Wilson JKV, Remick S, Tutsch KD. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol 199;9:2027-35.
35. Van Groeningen CJ, Pinedo HM, Heddes J, Kok RM, de Jong APJM, Wattel E, et al. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 1988;48:6956-61.
36. Wagner JG, Gyves JW, Stetson PL, Walker-Andrews SC, Wollner IS, Cochran MK, et al. Steady state non linear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res 1986;46:1499-506.
37. Wils JA. High dose fluorouracil: a new perspective in the treatment of colorectal cancer? Semin Oncol 1992;19 Suppl 3:126-30.
38. Yoshida T, Araki E, Ligo M, Takairo F, Mitsuya Y, Yasuhiro S, et al. Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother Pharmacol 1990;26:352-4.